Compare Cytokinetics Inc (CYTK) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Transocean Ltd — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Transocean Ltd trades at $5.54 (market cap $6.02B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Transocean Ltd is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Transocean Ltd for 18 Days on average.
| CYTK | RIG | |
|---|---|---|
Market Cap | $8.62B | $6.02B |
Volume | 2,594,626 | 19,180,005 |
Sector | Health | Energy |
52-Week High | $87.26 | $7.58 |
52-Week Low | $54.76 | $3.08 |
Typical Hold Time | 19 Days | 18 Days |
Enterprise Value | $8.72B | $10.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
RIG trades at $5.39, down 0.19% on the day, with a mixed technical picture showing bearish moving averages but neutral oscillators. The company reported a net loss of $2.92 billion in 2025, though revenue remains solid at $3.97 billion. Recent news highlights progress on the $5.8 billion Valaris acquisition and new contract wins, while analyst sentiment is divided with a 39% buy rating.
The outlook hinges on successful deleveraging and offshore cycle strength, but high debt and persistent losses pose significant risks. Investment appeal is speculative, dependent on cash flow improvements and debt reduction outweighing current profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
